Rosetta Genomics Q4 Revenues Slide 62 Percent | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced revenues for the fourth quarter dropped to $45,000 from $119,000 a year ago, a 62 percent retreat.

For the three months ended Dec. 31, 2010, the company posted a net loss of $3.7 million, or $.21 per share, an 8 percent decline from a little more than $4 million, $.28 per share, from the fourth quarter of 2009.

On a non-GAAP basis, Rosetta saw a loss of $.20 per share, down from $.25 per share a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.